Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aprinnova is a commercial-stage specialty ingredients company focused on sustainable beauty, personal care, and select health-related applications rather than therapeutic drug development. The company was formed as a joint venture between Amyris and NIKKOL Group to commercialize sugarcane-derived ingredients made using biotechnology and renewable chemistry. Its flagship products include Neossance Squalane and Neossance Hemisqualane, high-purity emollient and silicone-alternative ingredients used in cosmetics and personal care formulations, and it has also launched pharmaceutical-grade squalane/USP-grade material for regulated applications. Aprinnova leverages Amyris fermentation-based manufacturing capabilities together with NIKKOL's formulation and cosmetics-market expertise. The business appears to operate as a small, private, commercial ingredients company headquartered in Emeryville, California.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Aprinnova.